If you have a brokerage account that reaches the New York Stock Exchange, you can buy Waters stock under the ticker WAT, the only class of shares the company has registered there. What that share represents changed in February 2026: Waters, long known for chromatography columns and mass spectrometers, took over Becton Dickinson's biosciences and diagnostics businesses, and in the third quarter of 2026 those units produced about 51% of its revenue. Below: the business, the order, the missing dividend and the risks.
What Does Waters Do?
Waters makes instruments that split a sample into its parts, identify each one and measure how much is there, plus the consumables and service that keep them running. Its 10-K describes a company that "has pioneered innovations in chromatography, mass spectrometry and thermal analysis serving life, materials and food sciences for more than 65 years." Waters Corporation was organized in Delaware in 1991, went public in November 1995 and is based in Milford, Massachusetts.
The core technology is liquid chromatography (LC): a pressurized sample is pushed through a column packed with fine particles and comes out separated into its components. Besides HPLC systems, Waters has sold its faster ACQUITY UPLC line since 2004. Mass spectrometry (MS) then identifies molecules by their mass; most Waters mass spectrometers are built to sit behind an LC system, a pairing called LC-MS that drugmakers use to develop medicines and check each batch. Acquisitions widened the range: TA Instruments (1996) for thermal analysis, Micromass (1997) for mass spectrometry and Wyatt Technology (2023) for light scattering.
The largest deal closed on 9 February 2026. In a Reverse Morris Trust, Becton Dickinson (BD) spun off its Biosciences and Diagnostic Solutions businesses and merged them into a Waters subsidiary. Waters now runs four divisions. Analytical Sciences is the former Waters Division minus its clinical unit. Biosciences, formerly BD Biosciences, is described in the latest 10-Q as "a leader in flow cytometry solutions for immunology and cancer research and related clinical diagnostics." Advanced Diagnostics joins BD's former Diagnostic Solutions with the Waters clinical unit: microbiology, molecular diagnostics, cervical cancer screening and point-of-care tests. Materials Sciences is the former TA Division.
The 10-K names Agilent, Shimadzu, Bruker, Danaher and Thermo Fisher as principal competitors in the traditional Waters markets, and Danaher, Revvity, Cytek Biosciences and bioMérieux in the businesses from BD. For the other side of the transaction, see our Becton Dickinson stock guide.
How Waters Makes Money
In the third quarter of 2026, which ended on 3 October, the four divisions split revenue like this:
| Division | Share of Q3 2026 revenue | Former name | Main products |
|---|---|---|---|
| Analytical Sciences | 40% | Waters Division, excluding clinical | LC and LC-MS systems, columns, service |
| Advanced Diagnostics | 33% | BD Diagnostic Solutions plus Waters clinical | Microbiology, molecular and point-of-care tests |
| Biosciences | 22% | BD Biosciences | Flow cytometers and reagents |
| Materials Sciences | 5% | TA Division | Thermal analysis and rheology |
Shares are calculated from the earnings release; the financial statements combine Analytical Sciences and Materials Sciences into one reportable segment.
Full-year figures still describe the old Waters: the 2025 10-K was filed after the deal closed but reports the business before it. Net sales rose 7% in 2025; instruments made up about 43%, chemistry consumables about 20% and service about 38%. That puts about 57% in what Waters calls recurring revenue, which depends on how many instruments customers already run. Chemistry grew 12% on "the uptake in columns and application-specific testing kits to pharmaceutical customers."
Customers are concentrated by industry, not by name. In 2025, 59% of net sales went to pharmaceutical accounts, 30% to other industrial customers and 11% to academic and government labs, and no single customer took more than 2%. China accounted for about 14% of sales, the United States about 31% and Europe about 30%.
WAT Stock at a Glance
| Feature | WAT |
|---|---|
| Exchange | New York Stock Exchange |
| Ticker | WAT |
| Security | Common stock; Section 12(b) lists no other class |
| Sector | Life science tools and diagnostics |
| Index membership | S&P 500 |
| Headquarters | Milford, Massachusetts |
| Incorporated | Delaware, 1991 |
| Public since | November 1995 |
| Fiscal year | Ends 31 December |
| Payouts | No dividend; share buyback program authorized through January 2028 |
| SEC identifier | CIK 1000697 |
For live price and market value, see the Waters stock page on Bitbase.
How to Buy Waters Stock
Waters lists its own shares on the NYSE, so no depositary receipt applies: you buy the common stock itself.
1. Pick a broker with NYSE access. Outside the US, use a local firm selling US equities or a global broker; confirm which entity holds the account and who regulates it.
2. Open and verify the account. Most brokers ask investors outside the US for IRS Form W-8BEN, which the IRS tells you to submit "when requested by the withholding agent or payer."
3. Find the right line. Search WAT and confirm it reads Waters Corporation common stock on the NYSE.
4. Choose an order type. FINRA says a market order "provides the most certainty that your order will be executed," while a limit order executes only "at or better than a specified price."
5. Decide the size. Some brokers sell fractional shares, others limit them to "large-cap stocks or ETFs" or skip them, and FINRA notes: "As a fractional share owner, you might not have shareholder voting rights."
Taxes abroad. The IRS says "most types of U.S. source income received by a foreign person are subject to U.S. tax of 30%," a rate some tax treaties reduce. As Waters pays no dividend, there is currently nothing to withhold; any return comes from selling, taxed according to where you live.
Through funds. As an S&P 500 member, Waters sits in index funds like SPY from State Street, as one position among hundreds.
What Moves WAT Stock
Integrating BD's businesses. In the third quarter of 2026 the acquired units grew 1% against BD's figures for the year-earlier quarter, and chief executive Udit Batra said Waters is "delivering ahead of schedule on our synergy and integration commitments." Reported profit carries the cost of the deal: GAAP net income fell 46%, which the release attributes to purchase accounting charges, acquisition costs and restructuring, while adjusted earnings per share rose 21%.
Instrument replacement. Instrument orders follow capital budgets. In the same quarter Analytical Sciences instruments rose 9% and chemistry 10%, and Batra cited "instrument replacement trends, idiosyncratic growth drivers across GLP-1s, PFAS and India generics."
China. Sales there fell 10% in 2024, which the 10-K links to "increased government regulations and lower spending," then rose 10% in 2025. The filing also lists US-China trade tensions and tariffs, local competition and tighter procurement rules.
Funding and reimbursement. Academic labs depend on grants from agencies such as the US National Institutes of Health, and diagnostics demand partly depends on how hospitals and labs are reimbursed.
Where the BD Deal Adds Risk for WAT Holders
Item 1A of the 10-K opens with the acquisition:
Integration. "The Company's failure to successfully integrate the BDS Business within the expected timeline could adversely affect the Company's future results."
Debt. Waters assumed the borrowing that funded SpinCo's cash payment to BD, refinancing most of it with senior notes in March 2026. The 10-K calls that debt "substantial," saying it "could adversely affect the Company's operational flexibility and increase its borrowing costs."
Tax limits. For two years after the spin-off's cash distribution, a tax matters agreement means the company's "ability to engage in certain transactions, such as the issuance or purchase of stock or certain business combinations, may be limited."
Goodwill. A large part of the price was booked as goodwill, and the company "may be required to recognize impairment charges."
Research budgets. "Reductions in customers' research budgets or government funding may adversely affect the Company's business."
Above all that, one stock concentrates your risk in a single company, and with no dividend your whole return depends on the share price.
How to Research WAT Yourself
Waters files under CIK 1000697: the 10-K, three 10-Qs a year, and 8-Ks, including earnings releases, which in 2026 came on 9 February, 5 May, 4 August and 3 November. Quarters do not end on calendar month-ends: in 2026 the second and third closed on 4 July and 3 October, so check dates when comparing periods.
Within the 2025 10-K, Item 1 describes the deal and divisions, Item 1A the risks, Item 5 the dividend policy and Note 17 sales by product and region. Until the 2026 10-K, the first to include the BD businesses, releases compare them with BD's own prior-year figures.
For a larger rival, see our Thermo Fisher stock guide. Live prices are on the WAT page linked in the table; Bitbase's directory of US stock pages lists other companies.
Waters Stock FAQ
Can I buy Waters stock with crypto?
Not directly. A broker sells WAT only for US dollars, so crypto has to be converted to cash beforehand, a step that can trigger tax in some countries. You then hold a share with a vote in a registered company, one point in how a share differs from a crypto asset.
Does Waters pay a dividend?
No. The 10-K says Waters has not paid a dividend since its IPO and "does not intend to pay cash dividends in the foreseeable future." A buyback program is authorized through 21 January 2028, but there were no open-market repurchases in 2025 or the first half of 2026.
Why did I receive Waters shares from BD?
If you held BD stock on 5 February 2026, the spin-off record date, you received approximately 0.135 Waters shares per BD share, with cash for fractions. Former BD shareholders ended up with 39.2% of the combined company on a fully diluted basis.
Is WAT in the S&P 500?
Yes. On 6 November 2026, Waters Corp was listed among the holdings State Street published that day for SPY, its fund tracking the S&P 500.
Conclusion
Two businesses now sit behind a WAT share: since February 2026 it represents a lab instrument maker plus BD's former flow cytometry and diagnostics units, carrying new debt and tax limits and paying no dividend. Placing the order is the quick part; judging how the combination works out takes longer. Read the latest 10-Q and earnings release, watch how the acquired units grow, and decide what share of your portfolio a single lab-tools company deserves.
Related reading
Other Bitbase articles on this topic:
- How to Buy L3Harris Stock (LHX): Rocket Motors, Radios, Satellites
- How to Buy Mettler-Toledo Stock (MTD): Balances and Buybacks
- How to Buy Old Dominion Stock (ODFL): Union-Free LTL Freight
Disclaimer: This article is educational content from Bitbase Academy, provided for information only. It explains what a company or fund does and how the instruments referenced here differ from one another; it does not constitute investment, trading, tax, or financial advice, and it is neither a recommendation nor an endorsement of any security, token, or trading strategy. A tokenized stock is issued by a third party and is designed to give economic exposure to an underlying asset: it is not a share, it carries no shareholder rights, and it depends on the issuer's structure, eligibility rules, and redemption terms, which the issuer can change. Perpetual futures are leveraged derivatives that hold no underlying asset and can be liquidated, and trading hours, product availability, and eligibility differ by instrument and by jurisdiction and can change at any time. Written as of November 2026; verify everything yourself through company filings, the issuer's own documentation, and the product pages of the venue you trade on.
References
[1] Waters Form 10-K for 2025 (SEC EDGAR) www.sec.gov
[2] Waters 2025 Form 10-K, XBRL cover page (SEC EDGAR) www.sec.gov
[3] Waters Form 10-Q for the second quarter of 2026 (SEC EDGAR) www.sec.gov
[4] Waters third-quarter 2026 earnings release, filed with Form 8-K (SEC EDGAR) www.sec.gov
[5] Waters press release on completing the BD combination, Form 8-K (SEC EDGAR) www.sec.gov
[6] State Street SPDR S&P 500 ETF Trust (SPY): fund page and daily holdings www.ssga.com
[7] FINRA: Order Types www.finra.org
[8] FINRA: Investing in Fractional Shares www.finra.org
[9] IRS: NRA Withholding www.irs.gov
[10] IRS: About Form W-8 BEN www.irs.gov






